関連する実験動画

Updated: Feb 14, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.4K

CYP46A1 (CH24H) 阻害剤の発見のためのソチレステート誘導体に関する構造-活性関係研究

Xinwei Hu1,2, Wenqian Huang2,3,4, Xiaotong Lin2

  • 1Guangzhou University of Chinese Medicine, Guangzhou 510006, China.

Molecules (Basel, Switzerland)
|February 13, 2026
PubMed
まとめ

研究者は,ソチルスタット誘導体を設計することによって,ドラヴェット症候群とレノックス-ガストート症候群の新薬候補を探索しました. 3つの強力なCYP46A1阻害剤が発見され,これらの重度の性脳症候群に対する新しい治療法を提供しました.

キーワード:
CH24Hは,CH24Hと一致している.CYP46A1が使用されています.ドラヴェット症候群 (Dravet syndrome) とは,ドラヴェット症候群 (Dravet syndrome) とは,ドラヴェット症候群 (Dravet syndrome) とは,ドラヴェット症候群 (Dravet syndrome) とは,ドラヴェット症候群 (Dravet syndrome) とは,ドラヴェット症候群 (Dravet syndrome) とは,ドラヴェット症候群 (Dravet syndrome) とは,ドラヴェット症候群 (Dravet syndrome) とは,ドラヴェット症候群 (Dravet syndrome) とは,レノックス-ガストー症候群 (Lennox-Gastaut syndrome) とは,レノックス-ガストー症候群 (Lennox-Gastaut syndrome) とは,レノックス-ガストー症候群 (Lennox-Gastaut syndrome) とは,レノックス-ガストー症候群 (Lennox-Gastaut syndrome) とは,レノックス-ガストー症候群 (Lennox-Gastaut syndrome) とは,レノックス-ガストー症候群 (Lennox-Gastaut syndrome) とは,レノックス-ガストー症候群 (Lennox-Gastaut syndrome) とは,レノックス-ガストー症候群 (Lennox-Gastaut syndrome) とは,レノックス-ガストー症候群 (LGSA) とは,レノックス-ガストー症候群 (LGSA) とはソチール・ステート (Soticle Stat) とは構造と活動の関係である.

さらに関連する動画

Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors07:57

Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors

Published on: January 20, 2023

6.8K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.9K

関連する概念動画

Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.8K
Local Anesthetics: Chemistry and Structure-Activity Relationship01:30

Local Anesthetics: Chemistry and Structure-Activity Relationship

Local anesthetics (LAs) are drugs that induce a temporary loss of sensation in a limited body area, preventing pain. Cocaine was the first local anesthetic discovered in the late 19th century. Cocaine is a benzoic acid ester obtained from the leaves of coca shrubs and was often used for its psychotropic effects. Cocaine was first isolated in 1860 by Albert Niemann. Sigmund Freud studied the physiological actions of cocaine. Carl Koller later introduced it into clinical practice in 1884 as a...
6.8K
Cholinergic Antagonists: Chemistry and Structure-Activity Relationship01:29

Cholinergic Antagonists: Chemistry and Structure-Activity Relationship

Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic...
2.8K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.9K
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:29

Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
1.0K
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:22

Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
2.2K